SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 19, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




           Delaware                                    52-1555759
        (State of Incorporation)                     (I.R.S. Employer
                               Identification No.)



              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)


      Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 19, 1999:


FOR IMMEDIATE RELEASE
Contacts:
Mark E. Kaufmann                 Elliot Lebowitz, Ph.D.
Director, Planning and Analysis  President and Chief Executive
MedImmune, Inc.                  Officer
301-417-0770 x321                BioTransplant Incorporated
                                 617-241-5200
William C. Roberts               
Investor and Media Relations     Fran DeVellis or
MedImmune, Inc.                  Bruce Schiamberg
301-417-0770 x358                Feinstein Kean Partners
                                 617-577-8110
http://www.medimmune.com
http://www.biotransplant.
com
<PAGE>


          MEDIMMUNE AND BIOTRANSPLANT ANNOUNCE CLINICAL RESULTS AT
                 AMERICAN SOCIETY OF TRANSPLANTATION MEETING
- Companies Announce Results of BTI-322 Study; MedImmune Announces Results of
                                 CytoGam Study -


Gaithersburg,  MD, and Charlestown, MA, May 19, 1999 -- MedImmune, Inc. (Nasdaq:
MEDI) and BioTransplant  Incorporated (Nasdaq: BTRN) today announced preliminary
results of a Phase 1/2  clinical  trial in which  BTI-322  monoclonal  antibody,
given  in  combination  with  Prograf(Trademark)   (tacrolimus,   a  calcineurin
inhibitor;  Fujisawa)  after liver  transplantation,  significantly  lowered the
incidence of histological organ rejection compared to Prograf(Trademark)  alone.
The  data  from  the  study  were   presented   at  the   American   Society  of
Transplantation (AST) 18th Annual Scientific Meeting in Chicago.  MedImmune also
reported the results of another study,  also presented at AST, which showed that
CytoGam (Cytomegalovirus Immune Globulin Intravenous (Human);  CMV-IGIV),  given
after renal  transplantation in patients at high risk of  cytomegalovirus  (CMV)
infection,  significantly  lowered  the  incidence  of  several  markers  of CMV
infection and organ rejection  compared to standard  intravenous immune globulin
(IGIV).

The first study, by Jan P. Lerut, M.D., et al., "The Use Of Tacrolimus (TAC) And
Anti-CD2  Antibody  Lo-CD2a  (BTI-322)  In  Adult  Liver  Transplantation  (LT):
Preliminary  Results  Of A  Prospective  Randomized  Study,"  included  31 liver
transplant   recipients  who  received   combination   immunosuppression   using
Prograf(Trademark)  and low dose  steroids with or without a 10 day IV course of
BTI-322.  The results  indicated  that the  combined use of BTI-322 with Prograf
(Trademark)  lowered the  incidence of  histological  rejection in the immediate
post-operative  period by 70% compared to  Prograf(Trademark)  alone (24 percent
vs. 79 percent;  p=0.009)  without  increasing  the rates of  bacterial or viral
infection.

"A  monoclonal  antibody with the  properties of BTI-322 after liver  transplant
could  allow for easier  post-operative  care and  management  of these very ill
patients who are vulnerable to toxicity associated with calcineurin inhibitors,"
commented Dr. Lerut,  Professor of Surgery at Cliniques Saint Luc, University of
Louvain, Brussels.

"These data provide for an important  product  opportunity;  the available  data
suggest  the  ability  to  specifically  inhibit  the T  cell  response  against
transplant  antigens and  subsequently  prevent organ  rejection,"  added Elliot
Lebowitz,  Ph.D., President and Chief Executive Officer of BioTransplant.  "Both
BioTransplant   and  MedImmune   anticipate  that  the  same  activity  will  be
demonstrated  by  MEDI-507,  BTI-322's  humanized  sister  molecule,  now  being
evaluated in clinical  trials for treatment of acute  graft-versus-host  disease
and autoimmune disease.  Additionally,  both BTI-322 and MEDI-507 may play a key
role   in   BioTransplant's    ImmunoCognance(Trademark)    systems,   including
AlloMune(Trademark)  for human-to-human  transplants and XenoMune(Trademark) for
porcine-to-human transplants."

                                       1
<PAGE>


The second study,  "Efficacy Of CMV-IGIV  Versus Standard IGIV In Reducing Post-
Transplant CMV  Infection," by Hamid Shidban,  M.D., et al.,  reviewed  hospital
records of renal transplant  patients at high risk of primary CMV infection (CMV
seronegative   patients  who  received  CMV  seropositive   organs)  to  compare
CytoGam(n=48)  to standard IGIV (n=46) in reduction of markers  associated  with
organ rejection and post-transplant CMV infection. Compared to the standard IGIV
group,  the group that received  CytoGam had a significantly  lower incidence of
CMV  infection  (p=0.004),  rejection  rate at one  year  (p=0.04),  graft  loss
(p=0.0002)  and  mortality at one year  (p=0.03).  Dr.  Shidban is the Assistant
Professor  of Urology and  Medicine  at the  University  of Southern  California
School of Medicine.

"We are pleased to see that CytoGam reduces the risks faced by renal  transplant
patients,"  said Robert  Hirsch,  Ph.D.,  Vice  President of Medical  Affairs at
MedImmune.  "The results  confirm  CytoGam's  ability to prevent CMV  infection.
CytoGam is  indicated  for  prophylaxis  against  CMV  disease  associated  with
transplantation of kidney,  lung, liver,  pancreas,  and heart." Please see full
prescribing      information      for      CytoGam      attached      or      at
www.medimmune.com/products/cytopil.htm

BTI-322/MEDI-507
MEDI-507 is the humanized form of the murine monoclonal  antibody,  BTI-322.  In
pilot  clinical  trials in over 100  patients  in the United  States and Europe,
BTI-322 has suggested  potential clinical benefit in the studied populations and
has been  generally  well-tolerated.  In a Phase 1/2 clinical  trial  evaluating
BTI-322 for treatment of acute  graft-versus-host  disease (GvHD) in bone marrow
transplant (BMT) patients unresponsive to steroid therapy, the compound was well
tolerated and 55 percent of the patients responded positively to treatment, with
either a complete  response or a reduction  in grade of GvHD.  A Phase 1/2 trial
has been  completed for the  prevention of acute renal  transplant  rejection in
which  BTI-322  was given at the time of organ  transplantation.  Results of the
trial  suggested  a 58 percent  reduction  at two years  post-transplant  in the
incidence of kidney graft rejection  episodes  compared to  conventional  triple
drug  therapy  alone.  A trial  evaluating  MEDI-507  for  treatment  of GvHD in
steroid-resistant BMT patients has been completed and results are expected to be
presented at the  International  Society for  Hematology in Monaco in July.  Two
additional Phase 1/2 clinical trials have been developed to evaluate MEDI-507 as
treatment for acute GvHD in steroid-nave adult and pediatric patients.

Both MEDI-507 and BTI-322 bind specifically to the CD2 receptor found on T cells
and natural  killer (NK) cells.  Previous in vitro studies have  suggested  that
MEDI-507 has the ability to inhibit selectively the response of T cells directed
at transplant  antigens,  while  subsequently  allowing  immune cells to respond
normally to other antigens.  BTI-322 was initially discovered by Drs. Herv Bazin
and  Dominique  Latinne  at the  Experimental  Immunology  Unit of the  Catholic
University of Louvain in Belgium.

                                       2
<PAGE>

CytoGam
CytoGam is indicated  for  prophylaxis  against  cytomegalovirus  (CMV)  disease
associated with transplantation of kidney, lung, liver,  pancreas, and heart. In
transplants of these organs, other than kidney from CMV seropositive donors into
CMV  seronegative  recipients,  CytoGam should be considered in combination with
gancyclovir.  CytoGam is an intravenous  immune globulin  enriched in antibodies
against CMV.  CytoGam is made from human plasma and, like other plasma products,
carries the possibility for transmission of blood- borne viral agents.  The risk
of  transmission  of  recognized  blood-borne  viruses is  considered  to be low
because  of the  viral  inactivation  and  removal  procedures  employed  in the
manufacture of CytoGam. Minor reactions such as flushing, chills, muscle cramps,
back pain,  fever,  nausea,  vomiting,  arthralgia,  and wheezing  were the most
frequent  adverse  reactions  observed  during the  clinical  trials of CytoGam.
CytoGam is marketed by MedImmune  and  manufactured  by  Massachusetts  Biologic
Laboratories.

BioTransplant  Incorporated utilizes its proprietary technologies in reeducating
the body's immune  responses to allow  tolerance of foreign  cells,  tissues and
organs.  Based on this  technology,  the Company is  developing  a portfolio  of
products  designed to treat a range of medical  conditions,  including organ and
tissue  transplantation,  cancer  and  autoimmune  disease,  for  which  current
therapies  are  inadequate.  BioTransplant's  products  are  intended  to induce
long-term  functional   transplantation   tolerance  in  humans,   increase  the
therapeutic benefit of bone marrow transplants, and reduce or eliminate the need
for lifelong  immunosuppressive  therapy. MedImmune is developing MEDI-507 under
license  from  BioTransplant,  and  BioTransplant  has retained the right to use
BTI-322 and/or MEDI-507 in its proprietary  ImmunoCognance  (Trademark) systems,
which are designed to re-educate the immune system to accept foreign tissue: the
AlloMune(Trademark)   System  for   human-to-human   transplantation,   and  the
XenoMune(Trademark) System for porcine-to-human transplantation.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product  candidates in clinical trials.  In October
1995,   MedImmune  and  BioTransplant   established  a  strategic  alliance  for
development of BTI-322 and any future generation products, such as MEDI-507, for
use in organ transplantation and other indications.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                      ####





(REGISTRANT)      MEDIMMUNE, INC.




BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 19, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE AND BIOTRANSPLANT ANNOUNCES RESULTS", "secsgml_size_bytes": 12149}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99632460"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 19, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

           Delaware                                    52-1555759
        (State of Incorporation)                     (I.R.S. Employer
                               Identification No.)

              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)

      Registrant's telephone number, including area code (301) 417-0770

                No Exhibits are being filed with this report

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 19, 1999:

FOR IMMEDIATE RELEASE
Contacts:
Mark E. Kaufmann                 Elliot Lebowitz, Ph.D.
Director, Planning and Analysis  President and Chief Executive
MedImmune, Inc.                  Officer
301-417-0770 x321                BioTransplant Incorporated
                                 617-241-5200
William C. Roberts               
Investor and Media Relations     Fran DeVellis or
MedImmune, Inc.                  Bruce Schiamberg
301-417-0770 x358                Feinstein Kean Partners
                                 617-577-8110
http://www.medimmune.com
http://www.biotransplant.
com
MEDIMMUNE AND BIOTRANSPLANT ANNOUNCE CLINICAL RESULTS AT
                 AMERICAN SOCIETY OF TRANSPLANTATION MEETING
- Companies Announce Results of BTI-322 Study; MedImmune Announces Results of
                                 CytoGam Study -

Gaithersburg,  MD, and Charlestown, MA, May 19, 1999 -- MedImmune, Inc. (Nasdaq:
MEDI) and BioTransplant  Incorporated (Nasdaq: BTRN) today announced preliminary
results of a Phase 1/2  clinical  trial in which  BTI-322  monoclonal  antibody,
given  in  combination  with  Prograf(Trademark)   (tacrolimus,   a  calcineurin
inhibitor;  Fujisawa)  after liver  transplantation,  significantly  lowered the
incidence of histological organ rejection compared to Prograf(Trademark)  alone.
The  data  from  the  study  were   presented   at  the   American   Society  of
Transplantation (AST) 18th Annual Scientific Meeting in Chicago.  MedImmune also
reported the results of another study,  also presented at AST, which showed that
CytoGam (Cytomegalovirus Immune Globulin Intravenous (Human);  CMV-IGIV),  given
after renal  transplantation in patients at high risk of  cytomegalovirus  (CMV)
infection,  significantly  lowered  the  incidence  of  several  markers  of CMV
infection and organ rejection  compared to standard  intravenous immune globulin
(IGIV).

The first study, by Jan P. Lerut, M.D., et al., "The Use Of Tacrolimus (TAC) And
Anti-CD2  Antibody  Lo-CD2a  (BTI-322)  In  Adult  Liver  Transplantation  (LT):
Preliminary  Results  Of A  Prospective  Randomized  Study,"  included  31 liver
transplant   recipients  who  received   combination   immunosuppression   using
Prograf(Trademark)  and low dose  steroids with or without a 10 day IV course of
BTI-322.  The results  indicated  that the  combined use of BTI-322 with Prograf
(Trademark)  lowered the  incidence of  histological  rejection in the immediate
post-operative  period by 70% compared to  Prograf(Trademark)  alone (24 percent
vs. 79 percent;  p=0.009)  without  increasing  the rates of  bacterial or viral
infection.

"A  monoclonal  antibody with the  properties of BTI-322 after liver  transplant
could  allow for easier  post-operative  care and  management  of these very ill
patients who are vulnerable to toxicity associated with calcineurin inhibitors,"
commented Dr. Lerut,  Professor of Surgery at Cliniques Saint Luc, University of
Louvain, Brussels.

"These data provide for an important  product  opportunity;  the available  data
suggest  the  ability  to  specifically  inhibit  the T  cell  response  against
transplant  antigens and  subsequently  prevent organ  rejection,"  added Elliot
Lebowitz,  Ph.D., President and Chief Executive Officer of BioTransplant.  "Both
BioTransplant   and  MedImmune   anticipate  that  the  same  activity  will  be
demonstrated  by  MEDI-507,  BTI-322's  humanized  sister  molecule,  now  being
evaluated in clinical  trials for treatment of acute  graft-versus-host  disease
and autoimmune disease.  Additionally,  both BTI-322 and MEDI-507 may play a key
role   in   BioTransplant's    ImmunoCognance(Trademark)    systems,   including
AlloMune(Trademark)  for human-to-human  transplants and XenoMune(Trademark) for
porcine-to-human transplants."

                                       1
The second study,  "Efficacy Of CMV-IGIV  Versus Standard IGIV In Reducing Post-
Transplant CMV  Infection," by Hamid Shidban,  M.D., et al.,  reviewed  hospital
records of renal transplant  patients at high risk of primary CMV infection (CMV
seronegative   patients  who  received  CMV  seropositive   organs)  to  compare
CytoGam(n=48)  to standard IGIV (n=46) in reduction of markers  associated  with
organ rejection and post-transplant CMV infection. Compared to the standard IGIV
group,  the group that received  CytoGam had a significantly  lower incidence of
CMV  infection  (p=0.004),  rejection  rate at one  year  (p=0.04),  graft  loss
(p=0.0002)  and  mortality at one year  (p=0.03).  Dr.  Shidban is the Assistant
Professor  of Urology and  Medicine  at the  University  of Southern  California
School of Medicine.

"We are pleased to see that CytoGam reduces the risks faced by renal  transplant
patients,"  said Robert  Hirsch,  Ph.D.,  Vice  President of Medical  Affairs at
MedImmune.  "The results  confirm  CytoGam's  ability to prevent CMV  infection.
CytoGam is  indicated  for  prophylaxis  against  CMV  disease  associated  with
transplantation of kidney,  lung, liver,  pancreas,  and heart." Please see full
prescribing      information      for      CytoGam      attached      or      at
www.medimmune.com/products/cytopil.htm

BTI-322/MEDI-507
MEDI-507 is the humanized form of the murine monoclonal  antibody,  BTI-322.  In
pilot  clinical  trials in over 100  patients  in the United  States and Europe,
BTI-322 has suggested  potential clinical benefit in the studied populations and
has been  generally  well-tolerated.  In a Phase 1/2 clinical  trial  evaluating
BTI-322 for treatment of acute  graft-versus-host  disease (GvHD) in bone marrow
transplant (BMT) patients unresponsive to steroid therapy, the compound was well
tolerated and 55 percent of the patients responded positively to treatment, with
either a complete  response or a reduction  in grade of GvHD.  A Phase 1/2 trial
has been  completed for the  prevention of acute renal  transplant  rejection in
which  BTI-322  was given at the time of organ  transplantation.  Results of the
trial  suggested  a 58 percent  reduction  at two years  post-transplant  in the
incidence of kidney graft rejection  episodes  compared to  conventional  triple
drug  therapy  alone.  A trial  evaluating  MEDI-507  for  treatment  of GvHD in
steroid-resistant BMT patients has been completed and results are expected to be
presented at the  International  Society for  Hematology in Monaco in July.  Two
additional Phase 1/2 clinical trials have been developed to evaluate MEDI-507 as
treatment for acute GvHD in steroid-nave adult and pediatric patients.

Both MEDI-507 and BTI-322 bind specifically to the CD2 receptor found on T cells
and natural  killer (NK) cells.  Previous in vitro studies have  suggested  that
MEDI-507 has the ability to inhibit selectively the response of T cells directed
at transplant  antigens,  while  subsequently  allowing  immune cells to respond
normally to other antigens.  BTI-322 was initially discovered by Drs. Herv Bazin
and  Dominique  Latinne  at the  Experimental  Immunology  Unit of the  Catholic
University of Louvain in Belgium.

                                       2
CytoGam
CytoGam is indicated  for  prophylaxis  against  cytomegalovirus  (CMV)  disease
associated with transplantation of kidney, lung, liver,  pancreas, and heart. In
transplants of these organs, other than kidney from CMV seropositive donors into
CMV  seronegative  recipients,  CytoGam should be considered in combination with
gancyclovir.  CytoGam is an intravenous  immune globulin  enriched in antibodies
against CMV.  CytoGam is made from human plasma and, like other plasma products,
carries the possibility for transmission of blood- borne viral agents.  The risk
of  transmission  of  recognized  blood-borne  viruses is  considered  to be low
because  of the  viral  inactivation  and  removal  procedures  employed  in the
manufacture of CytoGam. Minor reactions such as flushing, chills, muscle cramps,
back pain,  fever,  nausea,  vomiting,  arthralgia,  and wheezing  were the most
frequent  adverse  reactions  observed  during the  clinical  trials of CytoGam.
CytoGam is marketed by MedImmune  and  manufactured  by  Massachusetts  Biologic
Laboratories.

BioTransplant  Incorporated utilizes its proprietary technologies in reeducating
the body's immune  responses to allow  tolerance of foreign  cells,  tissues and
organs.  Based on this  technology,  the Company is  developing  a portfolio  of
products  designed to treat a range of medical  conditions,  including organ and
tissue  transplantation,  cancer  and  autoimmune  disease,  for  which  current
therapies  are  inadequate.  BioTransplant's  products  are  intended  to induce
long-term  functional   transplantation   tolerance  in  humans,   increase  the
therapeutic benefit of bone marrow transplants, and reduce or eliminate the need
for lifelong  immunosuppressive  therapy. MedImmune is developing MEDI-507 under
license  from  BioTransplant,  and  BioTransplant  has retained the right to use
BTI-322 and/or MEDI-507 in its proprietary  ImmunoCognance  (Trademark) systems,
which are designed to re-educate the immune system to accept foreign tissue: the
AlloMune(Trademark)   System  for   human-to-human   transplantation,   and  the
XenoMune(Trademark) System for porcine-to-human transplantation.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product  candidates in clinical trials.  In October
1995,   MedImmune  and  BioTransplant   established  a  strategic  alliance  for
development of BTI-322 and any future generation products, such as MEDI-507, for
use in organ transplantation and other indications.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                      ####

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 19, 1999